Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Update

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the recipient of a large decline in short interest during the month of January. As of January 30th, there was short interest totaling 192,649 shares, a decline of 57.8% from the January 15th total of 456,520 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.

Wall Street Analyst Weigh In

Several research firms have weighed in on HNSBF. Wedbush started coverage on Hansa Biopharma AB (publ) in a report on Wednesday, January 7th. They issued an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating on shares of Hansa Biopharma AB (publ) in a report on Thursday. Finally, Jefferies Financial Group assumed coverage on shares of Hansa Biopharma AB (publ) in a research report on Wednesday, October 29th. They set a “buy” rating for the company. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy”.

Hansa Biopharma AB (publ) Price Performance

HNSBF remained flat at $2.91 during trading on Friday. The firm has a 50 day moving average price of $2.91 and a 200 day moving average price of $3.18. Hansa Biopharma AB has a twelve month low of $2.73 and a twelve month high of $4.58.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.